PAVmed (PAVM)

Its best-known assets are tied to esophageal disease detection. EsoGuard is a molecular diagnostic test designed to help identify precancerous changes associated with esophageal adenocarcinoma risk, while EsoCheck is a non-endoscopic cell collection device used to sample cells from the esophagus. These products are associated with Lucid Diagnostics, a PAVmed-affiliated business focused on tools for detecting esophageal precancer before it progresses to cancer. The approach seeks to provide an alternative to traditional endoscopy for appropriate patients and care settings.

PAVmed also develops the Veris Cancer Care Platform, a digital health and connected-care system intended to support cancer patients and clinicians through remote monitoring and data-driven care coordination. The company’s model combines product development, commercialization planning and corporate financing, which can make its results dependent on regulatory milestones, clinical adoption, reimbursement, capital availability and execution across several programs.

As a listed medtech company, PAVmed represents exposure to high-risk, innovation-oriented healthcare markets. Its value proposition rests on whether its diagnostic, device and digital health products can demonstrate clinical utility, secure payment pathways and gain adoption among physicians, health systems and patients.